Publications by authors named "Jamila H Champsi"
Article Synopsis
- - The study evaluated the prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) among Kaiser Permanente Northern California patients in the wake of the COVID-19 pandemic, involving nearly 10,000 adults.
- - An estimated 1.67% of participants reported ME/CFS-like illness, with about 14.12% of those cases occurring after a COVID-19 infection, particularly among unvaccinated individuals or those who had COVID-19 early in the pandemic.
- - Despite the findings, the overall impact of COVID-19 on increasing rates of ME/CFS-like illness appeared minimal during the study period, but those identified with the illness experienced significant impairments in multiple areas of functioning
Data guiding the duration and route of streptococcal bloodstream infection (BSI) treatment are lacking. We conducted a retrospective cohort study of adults hospitalized with uncomplicated streptococcal BSI in a large integrated healthcare system from 2013 to 2020. The exposures of interest were antibiotic duration (5-10 days vs.
View Article and Find Full Text PDFIntroduction: Centers of excellence and bundled payment models have driven perioperative optimization and surgical site infection (SSI) prevention with decolonization protocols and antibiotic prophylaxis strategies. We sought to evaluate time trends in the incidence of deep SSI and its causative organisms after six orthopaedic procedures in a US-based integrated healthcare system.
Methods: We conducted a population-level time-trend study using data from Kaiser Permanente's orthopaedic registries.
Article Synopsis
- Chronic hepatitis C virus (HCV) infection significantly increases the risk of developing various types of cancers, particularly liver cancer, compared to those without HCV.
- A study examining data from 2007 to 2017 found that individuals with HCV were more susceptible to several cancers, including hematologic, lung, pancreatic, oral, and anal cancers.
- Treatment with direct-acting antivirals (DAA) appears to lower the risk of liver and hematologic cancers in patients with HCV.
Among 25 291 and 4 921 830 people with and without hepatitis C, life expectancy at age 20 increased 1.8 years and 0.3 years from the interferon to interferon-free era, respectively.
View Article and Find Full Text PDFU.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with direct-acting antiviral agents (DAAs), but the high cost of DAAs may contribute to disparities in treatment uptake and outcomes.
View Article and Find Full Text PDFPrevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017.
Clin Gastroenterol Hepatol
February 2020
Article Synopsis
- Strategic planning for hepatitis C screening and treatment relies on accurate data about how often the virus clears on its own.
- Previous studies have reported spontaneous clearance rates of HCV between 15% and 60%.
- This 20-year observational study aimed to assess trends in HCV spontaneous clearance and identify factors linked to viremia in HCV-antibody-positive patients to better predict treatment needs.
Objectives: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation.
Methods: We conducted a retrospective cohort study of HCV-infected Kaiser Permanente Northern California members aged ≥18 during October 2014 to December 2016, using Poisson regression models to evaluate demographic, behavioral, and clinical factors associated with DAA initiation.
Background & Aims: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen.
Methods: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naïve, no cirrhosis, no HIV infection, level of HCV RNA <6 million IU/mL) and were treated for 8 or 12 weeks from October 2014 through December 2016.